Journal
CANCER LETTERS
Volume 232, Issue 2, Pages 139-147Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2005.02.002
Keywords
platelet-derived growth factor; central nervous systern; gliomas
Categories
Funding
- NCI NIH HHS [R01 CA09489, UO1CA894314-1] Funding Source: Medline
- NIGMS NIH HHS [GM07739] Funding Source: Medline
Ask authors/readers for more resources
Platelet-derived growth factor (PDGF) has long been implicated in cancer and is known to be involved in many biological processes. In Central Nervous System (CNS) neoplasms, particularly gliomas, PDGF is often over-expressed. However, what role PDGF plays in tumor progression remains to be fully described. A wide range of work from in vitro studies to mouse models have implicated the PDGF pathway in various processes including proliferation, cellular migration, development, and angiogenesis. Being a secreted factor, PDGF not only has autocrine effects on producing cells but also has potential for paracrine effects on other tumor cells and the tumor microenvironment. The development of small molecules that inhibit the PDGF receptor and various subsequent signaling components promises, to introduce new approaches to the treatment of gliomas. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available